Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi

NCT ID: NCT01041612

Last Updated: 2016-10-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-01-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this prospective, randomized multicenter study is to determine whether there is any difference in stent patency of covered metallic stents in terms of stent positioning, above and across the sphincter of Oddi, in malignant bile duct obstruction.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer of Bile Duct Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A: C-SEMS, inserted above SO

-In group A, SO should be preserved without sphincterotomy, but small infundibulotomy with needle knife can be accepted for cannulation.

Group Type ACTIVE_COMPARATOR

PTFE Covered ComVi [full covered] Biliary Stent

Intervention Type DEVICE

The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.

Group B: C-SEMS, inserted across SO

-In group B, small sphincterotomy (50% incision) will be done after biliary cannulation.

Group Type ACTIVE_COMPARATOR

PTFE Covered ComVi [full covered] Biliary Stent

Intervention Type DEVICE

The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PTFE Covered ComVi [full covered] Biliary Stent

The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.

Intervention Type DEVICE

PTFE Covered ComVi [full covered] Biliary Stent

The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PTFE Covered ComVi [full covered] Biliary Stent, Taewoong Medical, Korea PTFE Covered ComVi [full covered] Biliary Stent, Taewoong Medical, Korea

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Inoperable and/or unresectable cases of malignant stenosis at distal common hepatic duct or CBD, \>= 18 years old
* Bile duct or gallbladder cancer invading CBD or distal CHD
* Pancreatic cancer with mid or distal CBD invasion
* Cancer should be 1.5 cm apart from bifurcation and 2 cm apart from ampulla of Vater.
* First attempt of endoscopic biliary metallic stenting
* Negative history of biliary tract surgery
* Life expectancy at least longer than 4 months (Karnofsky score \>60%)

Exclusion Criteria

* Ampullary cancer
* Klatskin tumor
* Combined intrahepatic bile duct cancer
* Patient with hemobilia
* Previous history of biliary drainage (endoscopic, percutaneous, surgical) except plastic stent or endoscopic nasobiliary drainage smaller than 7 Fr within 14 days
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Taewoong Medical Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jong Taek, Lee

General manager

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dong Ki Lee, PH.D

Role: PRINCIPAL_INVESTIGATOR

Gangnam Severance Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gifu University

Gifu, , Japan

Site Status

Onomichi General Hospital

Onomichi, , Japan

Site Status

Teine-Keijinkai Hospital

Sapporo, , Japan

Site Status

The University of Tokyo

Tokyo, , Japan

Site Status

Toho University

Tokyo, , Japan

Site Status

Tokyo Medical University

Tokyo, , Japan

Site Status

Yamaguchi University

Ube, , Japan

Site Status

Soon Chun Hyang University School of Medicine

Bucheon-si, , South Korea

Site Status

Soon Chun Hyang University School of Medicine

Cheonan, , South Korea

Site Status

Catholic University of Daegu School of Medicine

Daegu, , South Korea

Site Status

Inha University School of Medicine

Incheon, , South Korea

Site Status

Gangnam Severance Hospital

Seoul, , South Korea

Site Status

Ajou University School of Medicine

Suwon, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Jung Nam Cho, Jimin Han, Ho Gak Kim, IM Hee Shin, Sang Heum Park, Jong Ho Moon, Jin Hong Kim, Don Haeng Lee, Iruru Maetani, Hiroyuki Maguchi, Keiji Hanada, Ichiro Yasuda, Takao Itoi, Hiroyuki Isayama, Dongki Lee. Prospective Randomized Trial Comparing Covered Metal Stent Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction. Gastrointestinal Endoscopy 77(58): AB139-AB140, 2013

Reference Type RESULT

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RaMM-BO 2.0

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.